Scotiabank raised the firm’s price target on Arcturus Therapeutics (ARCT) to $35 from $32 and keeps an Outperform rating on the shares. The company presented favorable interim results for ARCT-810 in ornithine transcarbamylase, OTC, deficiency across two phase 2 studies, the analyst tells investors. Overall, the firm believes Arcturus’ recent update validates the potential of the company’s therapeutics programs, which Scotiabank notes are underappreciated and can provide substantial upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating
- Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
- Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs
- Citi adds ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
- Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst